ArticleJournal of translational medicine2026
Hypoxic preconditioning drives metabolic reprogramming to increase the therapeutic efficacy of adipose mesenchymal stem cells in diabetic wounds.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypoxic pretreatment improves the efficacy of adipose-derived mesenchymal stem cells (ADSCs) in the repair of chronic refractory wounds; however, the underlying molecular mechanisms remain poorly understood. Energy metabolism serves as a crucial regulatory factor that influences stem cell fate, proliferation, and self-renewal capabilities. In this study, we established a diabetic skin wound model to systematically investigate the effects of the diabetic microenvironment and hypoxic pretreatment on the energy metabolism and functions of ADSCs, aiming to elucidate the role of adaptive metabolic regulation in increasing stem cell survival rates following transplantation.
methodsAn in vitro diabetic cell model was established to systematically evaluate the effects of high glucose and hypoxic preconditioning on the proliferation, migration, apoptosis, and cytokine secretion of ADSCs via PCR analysis and CCK-8, cell scratch, and apoptosis assays. The impact of high glucose and hypoxic preconditioning on the energy metabolism characteristics of ADSCs was investigated with a Seahorse XF Analyzer. The regulatory effects of the mTOR/HIF-1α signalling pathway on the energy metabolism and cellular functions of ADSCs was investigated via mTOR pathway inhibitors and siHIF transfection. The therapeutic efficacy of hypoxia preconditioned ADSCs in diabetic wound healing was determined by calculating wound healing rates and performing histopathological analyses.
resultsHypoxic preconditioning alleviated high glucose-induced functional impairments in ADSCs, including enhanced cell proliferation, migration, and cytokine secretion capacity, along with reduced apoptosis. Seahorse XF analysis revealed that high-glucose conditions suppressed glycolytic activity and impaired mitochondrial function, whereas hypoxic preconditioning upregulated glycolytic flux and optimized mitochondrial energy metabolism. Notably, cotreatment with mTOR pathway inhibitors or HIF-1α-targeting siRNA attenuated the beneficial effects of hypoxic preconditioning, particularly its regulatory impact on energy metabolism profiles. In vivo experiments confirmed that hypoxic-preconditioned ADSCs significantly improved therapeutic outcomes in diabetic skin wounds. However, these therapeutic enhancements were reversed upon coadministration of mTOR pathway inhibitors.
conclusionThe hyperglycaemic microenvironment in diabetic wounds disrupts cellular energy metabolism, while hypoxic preconditioning enhances the therapeutic efficacy of ADSCs in promoting diabetic wound repair by activating the mTOR/HIF-1α signalling pathway to remodel their energy metabolic profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.